Guest User
New Draft Guidance on Protocol Deviation ...

01/21/2025

-

The guidance breaks down the roles and responsibilities of the investigator, sponsor, and Institutional Review Board (IRB) in regards to monitoring, mitigating, reporting, and evaluating protocol deviations (PDs). The investigator, who is responsible for the conduct of the trial and protection of the rights, safety, and welfare of the participants must report all PDs to the sponsor, highlighting the important PDs.

New Draft Guidance on Protocol Deviation Management Part 2/2
Guest User
ICH E6(R3) Progresses into Step Four

01/15/2025

-

On January 6, 2025, the International Council of Harmonisation’s ICH E6(R3) for Good Clinical Practices (GCP) reached step four of the formal ICH procedure. This means that the ICH E6(R3) draft guidelines, since its release in May of 2023, were submitted to and approved by the ICH Regulatory Members of the ICH Assembly for adoption as an ICH Harmonised Guideline replacing E6(R2).

ICH E6(R3) Progresses into Step Four
Guest User
New Draft Guidance on Protocol Deviation ...

01/14/2025

-

On December 30, 2024, the US Food and Drug Administration (FDA) released the draft guidance for industry titled “Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices” to help trial sponsors, investigators, and institutional review boards (IRB) define, identify, and report protocol deviations.

New Draft Guidance on Protocol Deviation Management Part 1/2
Guest User
Implementing the New UK Clinical Trials ...

01/07/2025

-

The Health Research Authority (HRA) announced that England and Wales have begun implementing changes to their clinical trial regulations on June 1st, 2024. These changes include the removal of the requirement for trials to submit annual progress report to their Research Ethics Committee (REC) and the process of submitting safety reports. Scotland and Northern Ireland, following review, also implemented these changes to their regulations making the updates now applicable in all four of the UK nations as of August 1st, 2024.

Implementing the New UK Clinical Trials Regulations
Guest User
ICH E6(R3) Annex 2 Draft Version is Now ...

12/23/2024

-

On November 6th, 2024, the International Council of Harmonization (ICH) published the draft version of ICH E6(R3) Annex 2, a long awaited update to the good clinical practice (GCP) section of the ICH Harmonized Guidelines.

ICH E6(R3) Annex 2 Draft Version is Now Available!

Real World Evidence Aids Medical Device Approval

4/13/2021

-

The 21st Century Cures Act (PUBL255.PS (congress.gov), established December 13, 2016 “is designed to accelerate medical product development and bring new innovations and advances faster and more efficiently to them.” The Cures Act section 505F included the potential use of Real World Evidence (RWE). According to the FDA, Real World Evidence is “data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials and the “clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.” download (fda.gov) RWE establishes its evidence by using Real Word Data from medical billing claims, electronic health records, clinical registries, and mobile devices. This strategy provides more information on the safety and efficacy of a device beyond the limitations of a clinical trial.

Now Available for Purchase: An Overview of 21 CFR 50 Human Subject Protection and 21 CFR 56 IRB eLearning

4/06/2021

-

Now Available for Purchase: An Overview of 21 CFR 50 Human Subject Protection and 21 CFR 56 IRB eLearning

An Overview of 21 CFR 50 Human Subject Protection and 21 CFR 56 IRB interactive eLearning is now available for purchase in our online store HERE. The interactive eLearning course provides an overview of the key concepts and best practices for maintaining human subject protection (HSP) by following the U.S. Food and Drug Administration’s (FDA) applicable regulations. Conduct of a clinical trial involving human subjects includes considerations to protect their rights and safety. Ensuring HSP is a core principle of Good Clinical Practice (GCP) and is required by regulatory authorities. Understanding how to implement these FDA regulations applicable to clinical research is key to a successful and ethical clinical trial.

New FDA Sponsor-Investigator Warning Letter Sent Due to Insufficient CAPA

3/30/2021

-

What happens when an investigator or a sponsor of a clinical trial does not comply with FDA Code of Federal Regulations? And when they do not comply what needs to be done? Inadequate responses to inspection findings are very negatively impacting. Have you wondered how they are notified they are doing something wrong?

Background

The United States Food and Drug Administration (FDA) requires entities conducting clinical trials to go through steps for approval prior to beginning the trial. They also require adherence to several regulations. When these obligations are not met, it can be detrimental to study subjects, the public, and the integrity and quality of the data. The FDA sends warning letters to clinical research sponsors, investigators and other organizations outlining the errors that were made so they can take appropriate action. (About Warning and Close-Out Letters | FDA)

Visit Clinical Pathways, LLC.com to Hear Our Interview with MCC’s Executive Director Linda Sullivan

3/23/2021

-

Metrics Champion Consortium (MCC) has partnered with Clinical Pathways LLC to expand their eLearning courses on performance management and good clinical practice (GCP). This expansion will add 13 new eLearning courses to their program with more in development.

We sat down with Linda Sullivan, the Executive Director of the WCG - Metrics Champion Consortium (MCC), an industry consortium dedicated to bringing clinical research sponsors, vendors, and investigative sites together to collaboratively develop standardized performance.